OraSure Technologies develops rapid diagnostic tests and sample collection devices that enable decentralized and non-invasive testing. Its OraQuick line includes the first over-the-counter oral fluid rapid test approved for HIV antibody detection, with additional rapid tests for hepatitis C, COVID-19 and other infectious diseases. The company also provides specialized collection and stabilization kits for saliva, urine and fecal samples used in genomic, microbiome and molecular diagnostic applications by laboratories, public health organizations and researchers.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 31.2 | — | -19.7 | — |
| Q3 2025 | 27.1 | — | -13.7 | — |
| Q4 2025 | 26.8 | — | -19.3 | — |
| Q1 2026 | 27.9 | — | -22.4 | — |
| Q2 2026 | 30.6 | -1.9% | 6.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Palladyne AI Corp. (PDYN), HireQuest, Inc. (HQI), Eagle Financial Services, Inc. (EFSI), Globa Terra Acquisition Corporation (GTERA), Century Therapeutics, Inc. (IPSC), Standard BioTools Inc. (LAB)